2Verneris MR,Kornacker V,Mailander V,et ai.Resistance of ex vivo expanded CD3^+ CD56^+ T cells to Fas-mediated apoptposis.Cancer Immunol Immunother,2000,49:335-345.
3Dudley ME,Wunderlich R,Robbins PF,et al.Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.Science,2002,298:850-854.
4Schmidt-Wolf GD,Negrin RS,Schmidt-Wolf IG.Activated T cells and cytokine-induce CD3^+ CD56^+ killer cells.Ann Hematol,1997,74:51-56.
2Schmidt-Wolf IG, Negrin RS, Kiem HP, et ol. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity[J]. J Exp Med, 1991, 174(1): 139-491.
3Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3^+CD56^+ killer cells[J]. Ann Hematol, 1997, 74(2):51-56.
4Shi M, Fu J, Shi F, et al. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection[J]. Clin Immunol, 2009, 132(1):43-54.
5SIFT M, FU J, SHI F, et al. Transfusion of autologotm cyto- kitm- induced killer cells inhibits viral replication in patients with chronic hepatitis B vius infection [ J ]. Clin Immunol, 2009, 132(1 ) : 43 -54.
6卫生部医疗技术临床应用管理办法[M].北京:中华人民共和国卫生部.2009.
7HOOFNAGLE JH, DOO E, LIANG T J, et al. Management of hepatitis B: summary of a clinical research workshop [ J ]. Hepatology, 2007, 45 (4) : 1056 - 1075.
8SUN J, GAO Y, CHEN HS, et al. Transfusion of multi -factors activated immune cells as a novel treatment for patients with chronic hepatitis B [J]. J Clin Virol, 2006, 35(1}; 26-32.
9HADZIYANNIS S J, VASSlLOPOULOS D. Hepatitis B e anti- gen - negative chronic hepatitis B [ J ]. Hepatology, 2001,34 (4 Pt 1 ) ; 617 -624;.
10SCHMIDT-WOLF GD, NEGRIN RS, SCHMIDT-WOLF IG. Activated T cells and cytokine - induced CD3 CD56 killer cells[J]. Ann Hematol, 1997, 74(2) 51 -56.
